Ublituximab — TG Therapeutics’ potential blockbuster infusion for multiple sclerosis (MS) — is probably more clinically effective than the approved oral disease-modifying therapies but wouldn’t be cost-effective if priced the same as Roche’s Ocrevus at $55,081 per year.
Source: Drug Industry Daily